Making a case for albumin - A highly promising drug-delivery system

Future Medicinal Chemistry

Volumn 7, Issue 5, 2015, Pages 553-556

  Merlot, Angelica M ^a   Kalinowski, Danuta S ^a   Kovacevic, Zaklina ^a   Jansson, Patric J ^a   Lane, Darius J ^a   Huang, Michael L H ^a   Sahni, Sumit ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

albumin; diabetes; drug carriers; drug delivery; oncology; rheumatoid arthritis

Indexed keywords

ALBUMIN; DRUG CARRIER; ALBUMINOID; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; INSULIN;

DIABETES MELLITUS; DRUG DELIVERY SYSTEM; HUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; CHEMISTRY; METABOLISM; NEOPLASMS;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; DIABETES MELLITUS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS;

EID: 84930000089     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.15     Document Type: Review

References (26)

1. Peters T. All About Albumin: Biochemistry, Genetics and Medical Applications. Academic Press Inc, California, USA (1996).
2. Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 5, 299 (2014).
3. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract. Res. Clin. Anaesthesiol. 23(2), 183-191 (2009).
4. Aguirre Puig P, Orallo Moran MA, Pereira Matalobos D, Prieto Requeijo P. Current role of albumin in critical care. Rev. Esp. Anestesiol. Reanim. 61(9), 497-504 (2014).
5. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control.Release 132(3), 171-183 (2008).
6. Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J. Control. Release 161(2), 429-445 (2012).
7. Kratz F. A clinical update of using albumin as a drug vehicle - a commentary. J. Control. Release 190, 331-336 (2014).
8. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17-18), 812-818 (2006).
9. Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-Acting basal insulin analogs. Drug Healthc. Patient Saf. 2, 213-223 (2010).
10. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin. Pharmacokinet. 53(9), 787-800 (2014).
11. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes-A comprehensive review. Diabetes Technol. Ther. 12(1), 11-24 (2010).
12. Fleischmann RM, De Bruyn S, Duby C et al. A Novel individualized treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate. Arthritis Rheum. 64(10), S563 (2012).
13. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. J. Clin. Oncol. 30(17), 2055-2062 (2012).
14. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005).
15. ClinicalTrials.gov. NCT01730586 (2012).
16. ClinicalTrials.gov. NCT00583349 (2007).
17. ClinicalTrials.gov. NCT00995488 (2009).
18. ClinicalTrials.gov. NCT01827111 (2013).
19. ClinicalTrials.gov. NCT00731380 (2008).
20. ClinicalTrials.gov. NCT01307891 (2011).
21. Graeser R, Esser N, Unger H et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared with doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest. New Drugs 28(1), 14-19 (2010).
22. Mcdonagh CF, Huhalov A, Harms BD et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 11(3), 582-593 (2012).
23. Vis AN, Van Der Gaast A, Van Rhijn BW, Catsburg TK, Schmidt C, Mickisch GH. A phase II trial of methotrexatehuman serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother. Pharmacol. 49(4), 342-345 (2002).
24. Bolling C, Graefe T, Lubbing C et al. Phase II study of MTXHSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest. New Drugs 24(6), 521-527 (2006).
25. Flisiak R, Flisiak I. Albinterferon-Alpha 2b: a new treatment option for hepatitis C. Expert Opin. Biol. Ther. 10(10), 1509-1515 (2010).
26. Merlot AM, Sahni S, Lane DJR et al. Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget (2015) (In Press).